CombiGene AB (publ)
Stockholm Stock ExchangeTotal Valuation
CombiGene AB (publ) carries a market capitalization of 48.91M, placing it among publicly traded companies globally.
| Market Cap | 48.91M |
| Enterprise Value | N/A |
Share Statistics
CombiGene AB (publ) currently has 19.80M shares outstanding.
| Shares Outstanding | 19.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 144.56, and the price-to-book ratio stands at -1.07.
| PE Ratio | N/A |
| PS Ratio | 144.56 |
| PB Ratio | -1.07 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | -1.57 |
| P/OCF Ratio | -1.57 |
Financial Position
CombiGene AB (publ) maintains a current ratio of 17.47, meaning it holds 17.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 17.47 |
| Quick Ratio | 17.15 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -45.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
CombiGene AB (publ)'s stock has declined approximately -16.55405% over the past 52 weeks. The 50-day moving average sits at 2.48, while the 200-day moving average is 2.46.
| Beta (5Y) | N/A |
| 52-Week Price Change | -16.55405% |
| 50-Day Moving Average | 2.48 |
| 200-Day Moving Average | 2.46 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CombiGene AB (publ) generated 326,000.00 in revenue and converted that into -44.88M in net income, yielding earnings per share of -2.27. EBITDA reached -47.22M, while operating income came in at -47.22M.
| Revenue | 326,000.00 |
| Gross Profit | N/A |
| Operating Income | -47.22M |
| Pretax Income | -44.88M |
| Net Income | -44.88M |
| EBITDA | -47.22M |
| EBIT | -47.22M |
| Earnings Per Share (EPS) | -2.27 |
Balance Sheet
Total book value stands at -43.89M, with working capital of 70.82M providing operational flexibility.
| Cash & Cash Equivalents | 73.75M |
| Total Debt | N/A |
| Net Debt | -73.75M |
| Equity (Book Value) | -43.89M |
| Book Value Per Share | -2.22 |
| Working Capital | 70.82M |
Cash Flow
CombiGene AB (publ) produced -29.95M in operating cash flow over the past twelve months.
| Operating Cash Flow | -29.95M |
| Capital Expenditures | N/A |
| Free Cash Flow | -29.95M |
| FCF Per Share | -1.51 |
Margins
CombiGene AB (publ) operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -14,484.05 and net profit margin of -13,765.95 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -14,484.05 |
| Pretax Margin | -13,765.95 |
| Profit Margin | -13,765.95 |
| EBITDA Margin | -14,484.05 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -63.55 |
Stock Splits
CombiGene AB (publ)'s most recent stock split took place on June 7, 2021 with a 20:1 split ratio.
| Last Split Date | 6/7/2021 |
| Split Ratio | 20:1 |
Scores
CombiGene AB (publ) posts an Altman Z-Score of 4.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.82 |